Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.

AIMS The aim was to evaluate the clinical effectiveness, pharmacodynamics and pharmacokinetics of a range of Tincture of Opium (TOP) doses in the management of opioid withdrawal. METHODS Forty-five opium-dependent Thai subjects were allocated to three dosing groups (6.66, 13.3 and 20 mg morphine equivalents, twice daily) depending on their self-reported prior opium use. On day 5 of dosing subjects underwent an interdosing interval study where blood, withdrawal scores, heart rate and blood pressure (BP) were collected at 0, 1, 3 and 8 h. Plasma morphine concentrations were quantified by high-performance liquid chromatography, and plasma morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) concentrations by LCMS. RESULTS Thirty-two subjects completed the study. Withdrawal scores were low for all subjects (range 9-23% of maximum response). There were dose-dependent changes in both systolic and diastolic BP (P = 0.021 and P = 0.01, respectively), but these were not considered clinically significant. There were no effects of dose on respiratory rate. Plasma morphine concentrations changed significantly across the interdosing interval (P = 0.0001), rising to a maximum at 1 h after dosing. Plasma morphine concentrations also differed according to dose (P < 0.05). The mean ratios of the morphine glucuronides were found to be: M3G/M6G = 7.7, M3G/morphine = 35.6 and M6G/morphine = 4.9, values comparable to those previously reported. CONCLUSION The management of opioid withdrawal can be achieved, with minimal adverse effects, by using flexible dosing of TOP.

[1]  S. Donn,et al.  Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey , 2006, Journal of Perinatology.

[2]  M. Hellmich,et al.  Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. , 2005, Drug and alcohol dependence.

[3]  A. Somogyi,et al.  Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. , 2004, British journal of clinical pharmacology.

[4]  Crime..  WHO/UNODC/UNAIDS position paper. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. , 2004 .

[5]  L. Antonilli,et al.  High levels of morphine-6-glucuronide in street heroin addicts , 2003, Psychopharmacology.

[6]  L. Lagasse,et al.  Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. , 2002, The Journal of pediatrics.

[7]  Jason M. White,et al.  Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine , 2001, Pain.

[8]  M. Kreek,et al.  Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine , 2000, Annals of the New York Academy of Sciences.

[9]  A. Somogyi,et al.  Steady‐state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration‐effect relationships , 1999, Clinical pharmacology and therapeutics.

[10]  Jeff Ward,et al.  Role of maintenance treatment in opioid dependence , 1999, The Lancet.

[11]  L. Marsch.  The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. , 1998, Addiction.

[12]  A. Somogyi,et al.  Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. , 1997, Journal of pain and symptom management.

[13]  J. Bell,et al.  Methadone maintenance and drug-related crime. , 1997, Journal of substance abuse.

[14]  M. Gastpar,et al.  Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone , 1996, Addiction biology.

[15]  T. Hedner,et al.  Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration , 1995, Pain.

[16]  D Westerling,et al.  Plasma Concentrations of Morphine, Morphine‐3‐Glucuronide, and Morphine‐6‐Glucuronide After Intravenous and Oral Administration to Healthy Volunteers: Relationship to Nonanalgesic Actions , 1995, Therapeutic drug monitoring.

[17]  J. Tignol,et al.  A naturalistic follow-up study of French-speaking opiate-maintained heroin-addicted patients: effect on biopsychosocial status. , 1994, Journal of substance abuse treatment.

[18]  P. Stolley,et al.  Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. , 1993, Journal of acquired immune deficiency syndromes.

[19]  A. Somogyi,et al.  Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine , 1993, Clinical pharmacokinetics.

[20]  A. Somogyi,et al.  High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. , 1991, Journal of chromatography.

[21]  L. Öhlund,et al.  Mortality in heroin addiction: impact of methadone treatment , 1990, Acta psychiatrica Scandinavica.

[22]  J. Svensson,et al.  Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. , 1983, British journal of clinical pharmacology.

[23]  C. B. Christensen,et al.  Plasma morphine concentrations during chronic oral administration in patients with cancer pain , 1982, PAIN.

[24]  E. Änggård,et al.  Methadone maintenance: Plasma levels and therapeutic outcome , 1978, Clinical pharmacology and therapeutics.